Overview of T Cell Differentiation, Cytokines, and Immunologic Targets in Dermatology

Conclusions

• CD4 T-cell fate is determined by the cytokine environment at activation, producing distinct Th1, Th2, Th17, or regulatory responses with different immune functions.
• Th1 immunity is central for activating macrophages and supporting cytotoxic responses, and interferon-gamma is the key macrophage-activating cytokine.
• Strong Th1 responses promote granuloma formation and localized control of intracellular pathogens, whereas weak Th1 responses lead to disseminated disease such as lepromatous leprosy.
• Blocking upstream cytokines or checkpoints can be therapeutically useful, but broader inhibition may increase adverse effects, so more selective targeting is often preferable.
• Th2 responses drive B-cell class switching and humoral immunity, with cytokines such as IL-4, IL-5, and IL-13 directing antibody isotype changes.
• Defects in T-cell help for class switching, such as CD40/CD40L/FOXP3 pathway problems, lead to immunodeficiency or autoimmunity depending on the pathway affected.
• Regulatory T cells maintain peripheral tolerance through FOXP3, IL-10, and IL-2 consumption, and loss of this pathway can cause severe autoimmune syndromes like IPEX.
• JAK-STAT and TYK2 inhibitors can meaningfully modulate inflammatory skin disease, but JAK2-related spillover can cause hematologic toxicity.
• Complement is a major innate defense that promotes inflammation, opsonization, and membrane attack complex formation, with C5a as the strongest anaphylatoxin and C3b as the strongest opsonin.
• Complement regulatory defects can cause disease, including recurrent Neisseria infections when terminal components are absent and paroxysmal nocturnal hemoglobinuria when self-protection is lost.
• Toll-like receptors distinguish microbial patterns and trigger different inflammatory programs, with TLR2 sensing gram-positive bacteria, TLR4 sensing gram-negative LPS, and TLR7 sensing single-stranded RNA.
• Type I interferon signaling is important in autoimmune skin disease, and blocking IFNAR1 with anifrolumab may improve refractory dermatomyositis and lupus flares.
• Checkpoint inhibition has therapeutic value in cancer, but the talk emphasizes that manipulating these immune pathways is also highly relevant to dermatologic disease management.